$NVST

Analysts at Barclays and others updated views on healthcare stocks. Protagonist Therapeutics (PTGX): Barclays reiterated Buy, $153 target; TipRanks consensus Strong Buy, $133 average; TipRanks upgraded to Buy with $151 target. Qiagen (QGEN): Barclays Hold, $38 target; consensus Moderate Buy, $42.48. Envista Holdings (NVST): Barclays Buy, $32 target; consensus Moderate Buy, $30; BofA Buy, $34.

Envista Holdings (NYSE: NVST) reported Q2 CY2026 revenue of $730.5 million, up 7.1% year on year and about 2% above Wall Street estimates. Non-GAAP EPS was $0.41, up from $0.26 a year earlier, and 22.1% above consensus. Analysts expect next 12 months revenue growth of 1.1% and FY EPS around $1.47.

Envista Holdings Corp (NVST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nvst-ex991x7326xworkingfil.htm EX-99.1 Document Exhibit 99.1 Envista Reports Second Quarter 2026 Results BREA, Calif., August 5, 2026 / PRNewswire / -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended July 3, 2026. “We built on our

Envista Holdings (NYSE: NVST) will report earnings Wednesday after market hours. The company last quarter posted revenue of $705.5 million, up 14.4% year on year, and beat EPS and revenue expectations. For the upcoming quarter, analysts expect about 5% revenue growth. NVST trades near $27.37 with an average analyst price target of $29.43.

A Business Journal list of Orange County dental companies says PDS Health (formerly Pacific Dental Services) became the No. 1 dental firm by employee count, with 1,381 workers, up 6.8%. OC headcount fell 2% to 5,126. Envista drove much of the decline, while Envista reported 12-month revenue up 8% to $2.7B and shares up about 36% to above $28.

Ariel Investments highlighted Envista Holdings (NYSE:NVST). Barclays reiterated an Overweight rating but cut its price target to $32 from $34. The article cites Envista’s Q1 results: 9.5% core revenue growth, 25% adjusted EBITDA growth, and 50% EPS growth, with full-year guidance for sales +2% to +4%, adjusted EBITDA +7% to +13%, and EPS $1.35–$1.45.

Vanguard Capital Management has disclosed an 8,574,557-share stake in Envista Holdings Corp (NVST), representing 5.23% of the company's common stock as of March 31, 2026. This Schedule 13G filing indicates Vanguard holds sole dispositive power over all these shares and sole voting power over 1,255,976 shares. The investment is described as being in the ordinary course of business and not for the purpose of influencing control of the issuer.

Several healthcare and dental companies, including Envista, Baxter, Artivion, Dentsply Sirona, and Cigna, saw their stock prices fall after a February jobs report indicated an unexpected contraction in employment and significant job losses in the healthcare sector. This data has raised concerns among investors about a potential economic slowdown and decreased healthcare spending. Dentsply Sirona, in particular, experienced a 4.1% drop despite a recent 13.4% gain a week prior due to a revenue beat, though its full-year guidance was disappointing.

Envista Holdings (NYSE:NVST) delivered the strongest Q3 performance among tracked dental equipment and technology stocks, beating analyst revenue estimates significantly and achieving the fastest revenue growth. Henry Schein (NYSE:HSIC) and Align Technology (NYSE:ALGN) also reported strong quarters, with their stocks rising after earnings. Dentsply Sirona (NYSE:XRAY), however, had the weakest performance with declining revenues and missed EPS guidance.

Envista Holdings Corp's ( NYSE:NVST ) short interest as a percent of float has risen 12.74% since its last report. According to exchange reported data, there are now 10.26 million shares sold short, which is 7.52% of all regular shares that are available for trading.